Apart from a five per cent share of the Indian pharmaceutical market, the purchase of Ranbaxy will take Daiichi Sankyo way ahead of others in the race among Indian companies for patent-protected drugs. A recent paper on 'Patenting Landscape in India' by Evalueserve shows that Ranbaxy alone accounts for over 23 per cent of the total medicine patent applications filed by major domestic companies in India.
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
Shares of Ranbaxy Laboratories on Thursday fell 7.67 per cent on the Bombay Stock Exchange to Rs 552.25 at close, after top investment banks like JP Morgan and CLSA said the out-of-court settlement with Pfizer over cholesterol pill Lipitor announced on Wednesday would delay the launch of the drug in the US by well over a year.
Last month, the US Food and Drugs Administration had placed Wockhardt's facilities in Waluj near Aurangabad on import alert, barring supply of various products from these facilities to the US.
The rap from both the US and UK drug regulators, including the latest one from the latter, has hit the scrip.
Brokerages have cut the company's FY16 earnings estimates between 16% and 29% with target prices too coming down to the Rs 700-800 band
This is not just a Ranbaxy or Wockhardt problem, says K Satish Reddy
If the operating principle is that all members of a family must be given an equal role in the business and that they will not make way for better managers who are not members of the family (in other words, the feudal principle), it is hard to see such a company prospering for long in a competitive market.
He has already spearheaded eight significant acquisitions within and outside the country
Cipla tops pharma rankings with 5.42% market share, ahead of Ranbaxy and GSK.
The feud over Ranbaxy patriarch Bhai Mohan Singh's will deepened as Malvinder and Shivender duo (owners of Ranbaxy and Fortis respectively) and Manjit Singh issuing separate notices to the biggest beneficiary, Analjit Singh.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
An out-of-court settlement of the feud over Ranbaxy founder Bhai Mohan Singh's will is seemingly imminent between Analjit Singh and Malvinder, Shivender duo, the present promoters of Ranbaxy and Fortis respectively.
An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.
Lalit Ahluwalia, CFO, Ranbaxy North America, presents his views on the Indian Budget 2009 at Asia Society in New York.
I would focus on R&D, correct or fine tune the US strategy and look at inorganic growth routes
The US Food and Drug Administration (FDA) says it does not follow an India agenda.
Dilip Shanghvi founded Sun Pharma in 1983.
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
Take the rediff business quiz and see how much you know about India's pharmaceutical industry.
The weakness in the stock was because of inspections by the American drug regulator at its Halol plant in Gujarat which resulted in eight observations, as well as a downward revision of speciality drug payoffs.
Drug major Sun Pharmaceutical Industries has acquired US-based Pharmalucence Inc for an undisclosed amount.
With local companies facing stress in domestic operations, valuations are down.
Many say trend could lead to concerns on manufacturing quality in Indian facilities.
National Pharmaceutical Pricing Authority names Cipla, Dr Reddy's Labs and Ranbaxy among those.
Face NPPA fine for overcharging on anti-asthma drug
Finance Minister P Chidambaram has asked the Income Tax department to focus on the companies that pay less than effective tax rate of 24 per cent.
Entering Iran may lead to trouble for those having significant presence in the US market.
Not far back, in 2010, SRL Diagnostics, promoted by former Ranbaxy promoters Malvinder and Shivinder Singh, acquired the diagnostic services business of Piramal Healthcare for Rs 600 crore (Rs 6 billion).
At close, the Sensex was up 0.7% or 124 points at 18,789 and the Nifty gained 0.8% or 46 points to end at 5,565.
As Wal-Mart's disclosures on lobbying generated political heat in India, records with American House of Representatives show that around 27 Indian companies have spent money on lobbying in the US.
Disappointed with past experience, domestic majors even skip giving any memorandum.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances